In advanced stage lung cancer, frontline liquid biopsy testing is recommended for EGFR mutation detection when tumor tissue is insufficient (Paweletz et al. 2016; Lindeman et al. 2018; Rolfo et al. 2021; Satapathy & Singh et al. 2021), while it was strongly recommended for detection in TKI resistance settings (Satapathy & Singh et al. 2021; Silveira et al. 2021; Filipits et al. 2023). This evidence concerns the gene EGFR and neoplasm.